Janux Therapeutics doses first patient in Phase 1 JANX013
Janux Therapeutics says the first patient has been dosed in its Phase 1 trial evaluating JANX013, a PSMA-targeted tumor-activated CD28 co-stimulatory bispecific.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.